Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors

NCT03329001 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT03329001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03329001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
Lead sponsor
Tesaro, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 4, 2017
Completion date
June 15, 2023
Enrollment
236 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms